If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Form 8.3 - Silence Therapeutics plc

8 Sep 2010 13:02

RNS Number : 3588S
Smith & Williamson Investment Mngmt
08 September 2010
 



FORM 8.3

 

DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Identity of the person whose positions/dealings are being disclosed:

Smith & Williamson Investment Management Limited

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Silence Therapeutics plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

n/a

(e) Date position held/dealing undertaken:

7th September 2010

(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?

n/a

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

1p Ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

3,562,054

1.27%

(2) Derivatives (other than options):

(3) Options and agreements to purchase/sell:

 

TOTAL:

 

3,562,054

 

1.27%

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

n/a

Details, including nature of the rights concerned and relevant percentages:

n/a

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ordinary

Purchase

 

30,000

12.965p

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

n/a

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

n/a

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

n/a

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

n/a

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

None

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

No

 

 

Date of disclosure:

8th September 2010

Contact name:

Stephen Hamilton-Jones

Compliance Manager

Smith & Williamson Investment Management Limited.

Telephone number:

020 7131 4734

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETLVLFBBKFBBBF
Date   Source Headline
24th Apr 20094:35 pmRNSPrice Monitoring Extension
1st Apr 20097:00 amPRNUnaudited Preliminary Results
30th Mar 200912:15 pmPRNNotice of Results
27th Mar 20094:40 pmRNSSecond Price Monitoring Extn
27th Mar 20094:35 pmRNSPrice Monitoring Extension
19th Mar 20091:22 pmPRNHolding(s) in Company
16th Feb 20093:37 pmPRNHolding(s) in Company
21st Jan 20097:00 amPRNStatement re Patent Update
19th Jan 20091:00 pmPRNHolding(s) in Company
15th Jan 20093:00 pmPRNTotal Voting Rights
15th Jan 20099:45 amPRNHolding(s) in Company
13th Jan 20094:36 pmRNSPrice Monitoring Extension
12th Jan 20097:00 amPRNStatement re Change of operating address
9th Jan 200911:20 amPRNStatement re Patent Grant
8th Jan 20092:21 pmPRNResearch Update
8th Jan 200912:03 pmPRNIssue of Equity
5th Jan 20094:40 pmRNSSecond Price Monitoring Extn
5th Jan 20094:35 pmRNSPrice Monitoring Extension
2nd Jan 20094:35 pmRNSPrice Monitoring Extension
31st Dec 200812:40 pmRNSSecond Price Monitoring Extn
31st Dec 200812:36 pmRNSPrice Monitoring Extension
31st Dec 20087:00 amPRNTotal Voting Rights
18th Dec 20084:35 pmRNSPrice Monitoring Extension
12th Dec 20084:40 pmRNSSecond Price Monitoring Extn
12th Dec 20084:36 pmRNSPrice Monitoring Extension
11th Dec 20087:10 amPRNHolding(s) in Company
10th Dec 20087:00 amPRNStatement re Patent Decision
5th Dec 200812:05 pmPRNIssue of Equity
4th Dec 20087:00 amPRNResearch Update
1st Dec 20087:00 amPRNResearch Update
18th Nov 20087:00 amPRNStatement re Patent Issue
13th Nov 20081:00 pmPRNHolding(s) in Company
10th Nov 20084:44 pmRNSSecond Price Monitoring Extn
10th Nov 20084:37 pmRNSPrice Monitoring Extension
29th Oct 200811:00 amPRNHolding(s) in Company
27th Oct 20089:45 amPRNDirector/PDMR Shareholding
22nd Oct 200812:51 pmPRNDirector/PDMR Shareholding
22nd Oct 20087:00 amPRNDirector/PDMR Shareholding
17th Oct 20083:34 pmPRNAGM Statement
8th Oct 200810:15 amPRNHolding(s) in Company
26th Sep 20085:05 pmPRNDirector/PDMR Shareholding
26th Sep 200811:55 amPRNStatement re Intellectual Property
25th Sep 20087:00 amPRNHalf-yearly Report
24th Sep 200811:40 amPRNHolding(s) in Company
29th Aug 200812:15 pmPRNHolding(s) in Company
26th Aug 20085:11 pmPRNHolding(s) in Company
7th Aug 20088:57 amPRNHolding(s) in Company
5th Aug 20082:00 pmPRNHolding(s) in Company
31st Jul 20087:00 amPRNStatement re Notice of Patent Allowance
30th Jul 20084:25 pmPRNStatement re Notice of Patent Allowance

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.